Arcturus Therapeutics: Downgrading to "Hold" As CF Program Shifts Population Focus (ARCT)

Core Insights - The article discusses Arcturus Therapeutics Holdings Inc. and its ongoing development of LUNAR-CF for cystic fibrosis, with interim data expected in the first half of 2025 [2]. Group 1: Company Overview - Arcturus Therapeutics is focused on developing innovative therapies, particularly in the biotech sector [2]. - The company is part of a broader analysis service that provides insights into various pharmaceutical companies [1]. Group 2: Analyst Background - The analysis is conducted by Terry Chrisomalis, who has extensive experience in the biotech sector and utilizes an Applied Science background to inform investment decisions [2]. - The Biotech Analysis Central service includes a library of over 600 articles and a model portfolio of small and mid-cap stocks [2].